Prognosis method for blood disorders

A method for determining, in vitro, the risk for an individual of developing a blood disorder, from a biological sample of said individual, said method comprising the following steps:

• exposing said biological sample to mid-infrared radiation (MIR) of wavelength varying from 4000 cm−1 to 400 cm−1 to obtain a spectrum characteristic of said sample;
• processing said spectrum using Fourier transform followed by generating a second derivative of the Fourier transform in order to obtain a spectral signature made up of absorbance peaks characteristic due to their position, or wave number, and their intensity, or absorbance, of the type and the relative concentrations of the various molecules present in said sample;
• comparing said spectral signature obtained in the previous step with one or more reference spectral signatures, said one or more reference spectral signatures being obtained from a reference population of individuals and being processed using Fourier transform followed by generating a second derivative;
• and
• concluding that:
• (i) if the intensities of a first group of peaks of the spectral signature of said individual is significantly different from the intensities of these same peaks obtained in the reference spectral signature(s), that the individual is likely to develop a blood disorder,
• the first group of peaks corresponding to the wave numbers of the following first group:
• 1330 cm−1, 1445 cm−1, 1478 cm−1, 1493 cm−1, 1505 cm−1, 1507 cm−1, 1520 cm−1, 1526 cm−1, 1544 cm−1, 1571 cm−1, 1602 cm−1, 1668 cm−1, 1674 cm−1, 1676 cm−1, 1697 cm−1, and 2852 cm−1, and
• (ii) if not, that the individual is not likely to develop a blood disorder, and
• tracking the individual if the individual is likely to develop a blood disorder.